Skip to main content
ACR Convergence 2023 Main banner
Final Program


Schedule at a Glance
Legend
Session Format
In Person
In Person
Livestreamed
Livestreamed
On Demand
On Demand
Back

Alan J. Kivitz, MD

Altoona Center for Clinical Research
Duncansville, PA, United States

Pres Altoona Arthritis, Osteoporosis and Research Center

Presentation(s):

  • 0776: Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: 16- and 52-Week Results from a Randomized, Double-Blind, Phase 3 Study

    Sunday, November 12, 2023
    2:15 PM – 2:25 PM PT

    Disclosure(s): AbbVie/Abbott: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Amgen: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Chemocentryx: Officer or Board Member (Ongoing); Eli Lilly: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Frescenius Kabi: Consultant (Ongoing); Genzyme: Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Gilead: Consultant (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Grunenthal: Consultant (Ongoing); Horizon: Consultant (Ongoing), Officer or Board Member (Ongoing); Janssen: Consultant (Ongoing), Officer or Board Member (Ongoing); Novartis: Officer or Board Member (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Pfizer: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Selecta: Consultant (Ongoing); Takeda: Consultant (Ongoing); UCB: Officer or Board Member (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • L12: Efficacy and Safety Outcomes of TAK-279, a Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial in Patients with Active Psoriatic Arthritis

    Tuesday, November 14, 2023
    9:00 AM – 11:00 AM PT

    Disclosure information not submitted.